New York State Common Retirement Fund Has $29.80 Million Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

New York State Common Retirement Fund lowered its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 244,830 shares of the medical equipment provider’s stock after selling 2,847 shares during the quarter. New York State Common Retirement Fund’s holdings in Zimmer Biomet were worth $29,796,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of ZBH. American Century Companies Inc. grew its position in Zimmer Biomet by 21.2% in the 3rd quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock valued at $545,809,000 after purchasing an additional 852,186 shares during the period. Boston Partners grew its position in Zimmer Biomet by 29.2% in the 3rd quarter. Boston Partners now owns 2,694,832 shares of the medical equipment provider’s stock valued at $302,366,000 after purchasing an additional 608,959 shares during the period. Barclays PLC boosted its holdings in Zimmer Biomet by 129.2% during the 3rd quarter. Barclays PLC now owns 1,072,494 shares of the medical equipment provider’s stock worth $120,356,000 after acquiring an additional 604,652 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in Zimmer Biomet during the 3rd quarter worth $57,972,000. Finally, Jupiter Asset Management Ltd. purchased a new position in Zimmer Biomet during the 3rd quarter worth $50,763,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Down 1.2 %

ZBH opened at $119.75 on Friday. The company has a 50 day moving average of $126.09 and a 200 day moving average of $119.46. The company has a market cap of $24.60 billion, a PE ratio of 24.49, a price-to-earnings-growth ratio of 2.23 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $149.25. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping the consensus estimate of $2.15 by $0.05. The company had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. Zimmer Biomet’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period last year, the firm earned $1.88 EPS. On average, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.80%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet’s payout ratio is 19.63%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the transaction, the vice president now directly owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.95% of the company’s stock.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of analyst reports. Canaccord Genuity Group reaffirmed a “hold” rating and set a $130.00 price objective on shares of Zimmer Biomet in a report on Friday, February 23rd. Raymond James lifted their price objective on shares of Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Barclays lifted their price objective on shares of Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a report on Monday, February 12th. TheStreet upgraded Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. Finally, StockNews.com cut Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 19th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus target price of $139.39.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.